We are live on ! Find out more
COEPW

Coeptis Therapeutics Warrants

Delisted

COEPW was delisted on the 24th of April, 2026.

11 hedge funds and large institutions have $14.9K invested in Coeptis Therapeutics Warrants in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% less funds holding

Funds holding: 1311 (-2)

27.02% less ownership

Funds ownership: 27.02%0% (-27%)

41% less capital invested

Capital invested by funds: $25.1K → $14.9K (-$10.2K)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
11
Holders Change
-2
Holders Change %
-15.38%
% of All Funds
0.14%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
1
Reduced
4
Closed
3
Calls
Puts
Net Calls
Net Calls Change

COEPW Hedge Fund Activity: Q3 2025 in Review

11 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Coeptis Therapeutics Warrants (COEPW) for Q3 2025, worth a combined $14.9K — down 41% from $25.1K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of COEPW and 1 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 1 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $266. The largest seller was Meteora Capital, cutting an estimated $3.57K.

  • 11 institutional investors held Coeptis Therapeutics Warrants (COEPW) as of Q3 2025, down from 13 in Q2 2025.
  • Funds reported $14.9K of Coeptis Therapeutics Warrants stock for Q3 2025, down 41% quarter-over-quarter.
  • 1 fund opened new Coeptis Therapeutics Warrants positions in Q3 2025 and 3 closed out, a net change of -2 holders.
  • The largest Coeptis Therapeutics Warrants buyer in Q3 2025 was Citadel Advisors, an estimated $266 added.
  • The largest Coeptis Therapeutics Warrants seller in Q3 2025 was Meteora Capital, an estimated $3.57K sold.

Based on aggregated 13F filings for Q3 2025.